Remove 2029 Remove Communication Remove Immunity
article thumbnail

Intercept receives orphan drug designation for liver disease combo therapy

Pharmaceutical Technology

Primary biliary cholangitis is a rare autoimmune disease where small bile ducts are injured by the patient’s own immune system. billion in 2029. This results in bile buildup in the liver and can lead to scarring. The condition gradually worsens and can result in liver failure. Please check your email to download the Report.

article thumbnail

AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline

Pharmaceutical Technology

A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an ‘immune reset’ by repopulation of healthy B cells. We may still continue to send you service-related and other non-promotional communications. higher at $185.62 on 30 June, the day the announcement was made.

article thumbnail

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Pharmaceutical Technology

Find out more According to GlobalData’s Acute Lymphocytic Leukemia: Epidemiology Forecast to 2029 report, the number of diagnosed incident cases in the eight major markets (8MM: China, France, Germany, Italy, Japan, Spain, the UK and the US) is projected to increase from 25,636 in 2025 to 26,482 by 2029 at an annual growth rate of 1.16%.